Table 1.
Description of the prospective and retrospective cohorts used in the study. Retrospective cohort related to Figure 1; Prospective cohort related to Figures 2–4.
| Retrospective Cohort | Prospective Cohort | ||||||
|---|---|---|---|---|---|---|---|
| Total number of patients |
215 | 26 | |||||
| Gender | Female | 215 | 25 (96%) | ||||
| Male | 0 | 1 (4%) | |||||
| Date of Inclusion | 2004–2012 | 2013–2020 | |||||
| Mean follow-up (years) | 7.7 | 1.5 | |||||
| Mean age at diagnosis (years) | 55 (22 min–87 max) |
53 (29 min–76 max) |
|||||
| I | 41 (19%) | 3 (11%) | |||||
| Histological grade | II III | 67 (31%) 105 (49%) |
9 (35%) 13 (50%) |
||||
| NA | 2 (1%) | 1 (4%) | |||||
| pT0 | 0 | 3 (11%) | |||||
| pT1 | 146 (68%) | 10 (39%) | |||||
| Pathological tumor | pT2 | 62 (29%) | 11 (42%) | ||||
| size (pT) | pT3 | 4 (1.5%) | 1 (4%) | ||||
| pT4 | 3 (1.5%) | 0 | |||||
| NA | 0 | 1 (4%) | |||||
| Pathological Lymph node status (pN) | Negative Positive NA | 127 (59%) 86 (40%) 2 (1%) |
21 (81%) 4 (15%) 1 (4%) |
||||
| Metastatic status | Negative Positive NA | 203 (94%) 3 (2%) 9 (4%) |
25 (96%) 0 1 (4%) |
||||
| Mean tumor size (mm) | 19 | 23.7 | |||||
| Lum A | 96 (45%) | 9 (35%) | |||||
| Breast cancer subtype | Lum B HER2 |
- 54 (25%) |
3 (11.5%) 3 (11.5%) |
||||
| TN | 65 (30%) | 11 (42%) | |||||
| CAF-S1 | 32 (15%) | - | |||||
| CAF-S2 | 38 (18%) | - | |||||
| CAF enrichment | CAF-S3 | 3 (1%) | - | ||||
| CAF-S4 | 111 (52%) | - | |||||
| NA | 31 (14%) | - | |||||
| CAF-S1 | CAF-S2 | CAF-S3 | CAF-S4 | NA | |||
| CAF enrichment in breast cancer subtypes | LumA HER2 | 6 (6%) |
34 (35%) |
1 (1%) |
40 (42%) |
15 (16%) |
- - |
| 9 (17%) |
2 (3%) |
1 (2%) |
33 (61%) |
9 (17%) |
|||
| TN | 16 | 2 | 1 | 38 | 8 | - | |
| (25%) | (3%) | (1%) | (59%) | (12%) | |||
| Yes | 85 (39%) | 11 (42%) | |||||
| Hormonotherapy | No | 126 (59%) | 0 | ||||
| NA | 4 (2%) | 15 (58%) | |||||
| Yes | 204 (95%) | 21 (81%) | |||||
| Radiotherapy | No | 0 | 4 (15%) | ||||
| NA | 11 (5%) | 1 (4%) | |||||
| Yes | 141 (66%) | 19 (73%) | |||||
| Chemotherapy | No | 0 | 0 | ||||
| NA | 74 (34%) | 7 (27%) | |||||
| Yes | 45 (21%) | 2 (8%) | |||||
| Targeted therapy | No | 0 | 0 | ||||
| NA | 170 (79%) | 24 (92%) | |||||
List of abbreviations: pT: Pathological tumor size; pN: Pathological Lymph node status: mm: millimeters; Breast cancer subtypes: Lum A/B: Luminal A/B; HER2: Human epidermal growth factor receptor 2; TN: Triple Negative; NA: Not available.